Can a common diabetes drug work safely in kidney patients?
NCT ID NCT02895750
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested the safety and effectiveness of metformin extended release (XR) in 12 adults with type 2 diabetes and mild to moderate chronic kidney disease (stages 1 to 3). Participants took metformin XR tablets for 6 to 12 weeks, and researchers monitored their blood glucose levels continuously. The goal was to see if the drug could control blood sugar without causing harm, especially to the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metformin extended release (XR)
What this could lead to
If successful, this could show that metformin XR is safe and effective for managing blood sugar in type 2 diabetes patients with mild to moderate kidney disease.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply broadly. Metformin can rarely cause lactic acidosis, especially in kidney disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Amiens Picardie
Amiens, 80054, France